Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roemer

Showing results (131-140 of 165) with videos related to

Pageof 17
Sort By:
Blood|December 5, 2018
Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphomaMatias Mendeville, Margaretha G M Roemer, Mari F C M van den Hout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2013
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignanciesBenjamin J Chen, Bjoern Chapuy, Jing Ouyang, et al.
Iscience|August 4, 2023
Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphomaMargaretha G M Roemer, Tim van de Brug, Erik Bosch, et al.
Blood|September 13, 2017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, et al.
Experimental Dermatology|September 2, 2024
Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patientsS Melchers, M Roemer, J D Albrecht, et al.
Frontiers in Immunology|January 11, 2021
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker PotentialJossie Rotman, Leontine A S den Otter, Maaike C G Bleeker, et al.
Cancer Cell|December 17, 2013
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphomaBjoern Chapuy, Michael R McKeown, Charles Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Cancer Immunology Research|October 15, 2016
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusMargaretha G M Roemer, Ranjana H Advani, Robert A Redd, et al.
Blood Cancer Journal|February 19, 2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, et al.
Pageof 17

Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Blood|December 5, 2018
Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphomaMatias Mendeville, Margaretha G M Roemer, Mari F C M van den Hout, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2013
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignanciesBenjamin J Chen, Bjoern Chapuy, Jing Ouyang, et al.
Iscience|August 4, 2023
Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphomaMargaretha G M Roemer, Tim van de Brug, Erik Bosch, et al.
Blood|September 13, 2017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, et al.
Experimental Dermatology|September 2, 2024
Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patientsS Melchers, M Roemer, J D Albrecht, et al.
Frontiers in Immunology|January 11, 2021
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker PotentialJossie Rotman, Leontine A S den Otter, Maaike C G Bleeker, et al.
Cancer Cell|December 17, 2013
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphomaBjoern Chapuy, Michael R McKeown, Charles Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Cancer Immunology Research|October 15, 2016
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusMargaretha G M Roemer, Ranjana H Advani, Robert A Redd, et al.
Blood Cancer Journal|February 19, 2021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, et al.
Pageof 17